| Specificity |
The product is specific for human IFN-γ. This antibody binds with recombinant IFN-γ protein in ELISA and Western blot assay. The antibody is recommended as a detection antibody in Sandwich ELISA assay with capture antibody GenScript, A01898-40, Human IFN-γ Antibody (21G2), mAb, Mouse. |
| Host Species |
Mouse |
| Immunogen |
Recombinant human IFN-γ |
| Conjugate |
Biotin |
|
Working concentrations for specific applications should be determined by the investigators. The appropriate concentration may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. |
| Application |
Recommended Usage |
| ELISA |
0.01-0.05 µg/ml |
| Western Blot |
1 µg/ml |
|
| Form |
Lyophilized |
| Storage Buffer |
lyophilized with PBS, pH 7.4, containing 1% BSA and 0.02% sodium azide. |
| Reconstitution |
Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL. |
| Storage Instructions |
The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles. |
| Purification |
Protein A affinity column |
| Isotype |
Mouse IgG1,κ |
| Clonality |
Monoclonal |
| Clone ID |
16F3 |
| Note |
GenScript can customize this product per customer's request including product size, buffer components, etc. |
| Target Background |
Interferon-γ (IFN-γ) is a pro-inflammatory cytokine that is central in host resistance to infection. It is mainly produced by natural killer cells and CD4+ and CD8+ T cells. Its receptors are found on nearly all cells, where it activates diverse responses that enable potential host cells to prevent invasive infection by bacteria, parasites, and viruses. Takayanagi et al. (2000) demonstrated that IFN-γ strongly suppresses osteoclastogenesis by interfering with the RANKL (602642)-RANK (603499) signaling pathway. Tsubota et al. (1999) reported that this upregulation in Sjogren syndrome patients may be controlled by interferon-gamma through the activation of transcription factor NF-KB. |
| Synonyms |
Mouse monoclonal to IFNG,IFG,IFI,IFN-gamma,interferon gamma,Immune Interferon |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
